Logo
x

Search

Subscribe Now

Initiates

TG Therapeutics Initiates Patient Enrolment in P-III ULTRA-V Trial for Triple Combination Regimen to Treat R/R Chronic Lymphocytic Leukemia

TG Therapeutics Initiates Patient Enrolment in P-III ULTRA-V Trial for Triple Combination Regimen to Treat R/R Chronic Lymphocytic...

  • April 22, 2021
Daiichi Sankyo Initiates P-II Trial of Pexidartinib for Tenosynovial Giant Cell Tumor in Japan

Daiichi Sankyo Initiates P-II Trial of Pexidartinib for Tenosynovial Giant Cell Tumor in Japan

  • April 12, 2021
Evotec and Exscientia Initiate Human Clinical Trials of their Novel Immuno-Oncology Drug

Evotec and Exscientia Initiate Human Clinical Trials of their Novel Immuno-Oncology Drug

  • April 9, 2021
Tetra Bio-Pharma Initiates Additional Studies of ARDS-003 in Neuroinflammation and Antiviral Diseases

Tetra Bio-Pharma Initiates Additional Studies of ARDS-003 in Neuroinflammation and Antiviral Diseases

  • March 26, 2021
Pfizer and BioNTech Initiate COVID-19 Vaccine Trial in Children Under 12

Pfizer and BioNTech Initiate COVID-19 Vaccine Trial in Children Under 12

  • March 26, 2021
GSK Initiates P-III Study of GSK3511294 (GSK'294) for the Treatment of Severe Asthma

GSK Initiates P-III Study of GSK3511294 (GSK'294) for the Treatment of Severe Asthma

  • March 18, 2021
Samsung Bioepis Initiates P-I Study of SB17 Proposed Biosimilar to Stelara (ustekinumab)

    Samsung Bioepis Initiates P-I Study of SB17 Proposed Biosimilar to Stelara (ustekinumab)

    • March 2, 2021
    GSK Initiates P-III study for RSV Candidate Vaccine Programme for Older Adults

      GSK Initiates P-III study for RSV Candidate Vaccine Programme for Older Adults

      • February 17, 2021
      Celltrion Initiates P-III Study of CT-P42 (biosimilar- aflibercept)

        Celltrion Initiates P-III Study of CT-P42 (biosimilar- aflibercept)

        • February 8, 2021
        Daiichi Sankyo Initiates P-II Study of Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC

          Daiichi Sankyo Initiates P-II Study of Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC

          • February 4, 2021
          Covaxx Initiates P-II Trial of UB-612 Against COVID-19 in Taiwan

            Covaxx Initiates P-II Trial of UB-612 Against COVID-19 in Taiwan

            • February 3, 2021
            Janssen Initiates Rolling Submission of BLA to US FDA of Autoleucel (cilta-cel) to Treat Multiple Myeloma

              Janssen Initiates Rolling Submission of BLA to US FDA of Autoleucel (cilta-cel) to Treat Multiple Myeloma

              • December 23, 2020
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.